Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

You are viewing this page in draft mode.

The search for Alzheimer disease therapeutics — same targets, better trials?

Despite negative findings from numerous clinical trials of potential disease-modifying therapies for Alzheimer disease, amyloid remains the most compelling therapeutic target. Advances in biomarker methods now enable accurate monitoring of Alzheimer disease progression from the earliest stages of the disease. We must therefore redouble efforts to find an effective treatment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37–43 (2014).

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Knopman, D. S. Lowering of amyloid-β by β-secretase inhibitors — some informative failures. N. Engl. J. Med. 380, 1476–1478 (2019).

    CAS  PubMed  Google Scholar 

  4. 4.

    Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305–2316 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Klein, G. et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res. Ther. 11, 101 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333 (2014).

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Moussa-Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H. & Al-Tel, T. H. BACE1 inhibitors: Current status and future directions in treating Alzheimer’s disease. Med. Res. Rev. 40, 339–384 (2020).

    PubMed  Google Scholar 

  8. 8.

    Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012).

    CAS  PubMed  Google Scholar 

  9. 9.

    Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Ulland, T. K. & Colonna, M. TREM2 - a key player in microglial biology and Alzheimer disease. Nat. Rev. Neurol. 14, 667–675 (2018).

    CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Michael S. Rafii.

Ethics declarations

Competing interests

M.S.R. has served as consultant to AC Immune. P.S.A. has received research support from Lilly, Janssen, Eisai, the Alzheimer’s Association, NIH and FNIH, and has consulted for Merck, Biogen, Roche and ImmunoBrain Checkpoint.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rafii, M.S., Aisen, P.S. The search for Alzheimer disease therapeutics — same targets, better trials?. Nat Rev Neurol 16, 597–598 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing